Humanwell Healthcare (600079.SH): Abiraterone acetate tablets obtained drug registration certificate.
Renfu Pharmaceutical (600079.SH) announced that its subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd....
Humanwell Healthcare (600079.SH) announced that its controlling subsidiary, Wuhan Jiulong Renfu Pharmaceutical Co., Ltd., recently received the "Drug Registration Certificate" issued by the National Medical Products Administration for Acetate Abiraterone Tablets. Acetate Abiraterone Tablets are used in combination with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC), including those who have not received hormone therapy or have received hormone therapy for no more than 3 months.
Related Articles
The lifting of restrictions on restricted shares tests the fundamentals of STAR SPORTS MED (01609), and with sustained performance growth, the valuation has entered a reasonable range.
MNSO (09896) repurchased 107,400 shares for US$236,800 on October 2.
BUD APAC (01876): Internal restructuring generates US$52 million tax expense; additionally, a US$30 million provision is made for Indian receivables.
The lifting of restrictions on restricted shares tests the fundamentals of STAR SPORTS MED (01609), and with sustained performance growth, the valuation has entered a reasonable range.
MNSO (09896) repurchased 107,400 shares for US$236,800 on October 2.
BUD APAC (01876): Internal restructuring generates US$52 million tax expense; additionally, a US$30 million provision is made for Indian receivables.
